Synaptogenix Morgan Bond
SNPX Stock | USD 2.88 0.02 0.69% |
Net Debt To EBITDA is likely to rise to 3.62 in 2024, whereas Net Debt is likely to drop (30.1 M) in 2024. With a high degree of financial leverage come high-interest payments, which usually reduce Synaptogenix's Earnings Per Share (EPS).
Debt Ratio | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.0 |
Synaptogenix |
Given the importance of Synaptogenix's capital structure, the first step in the capital decision process is for the management of Synaptogenix to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Synaptogenix to issue bonds at a reasonable cost.
Popular Name | Synaptogenix Morgan Stanley 3971 |
Specialization | Pharmaceuticals, Biotechnology & Life Sciences |
Equity ISIN Code | US87167T2015 |
Bond Issue ISIN Code | US61744YAL20 |
S&P Rating | Others |
Maturity Date | 22nd of July 2038 |
Issuance Date | 24th of July 2017 |
Coupon | 3.971 % |
Synaptogenix Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
SNV 5625 15 FEB 28 | US87164DVJ61 | Details | |
SYNCHRONY FINL 45 | US87165BAG86 | Details | |
SYNCHRONY FINL 395 | US87165BAM54 | Details | |
SYNCHRONY FINL 37 | US87165BAL71 | Details | |
SYF 4875 13 JUN 25 | US87165BAS25 | Details | |
SYF 2875 28 OCT 31 | US87165BAR42 | Details | |
SYF 725 02 FEB 33 | US87165BAU70 | Details | |
SNX 265 09 AUG 31 | US87162WAK62 | Details | |
SNX 175 09 AUG 26 | US87162WAF77 | Details | |
Synovus 59 percent | US87161CAM73 | Details | |
SNV 52 11 AUG 25 | US87161CAN56 | Details | |
SYNNVX 4892 24 APR 25 | US87164KAG94 | Details | |
Morgan Stanley 3591 | US61744YAK47 | Details | |
Morgan Stanley 3971 | US61744YAL20 | Details | |
SYF 54 22 AUG 25 | US87166FAD50 | Details | |
SYF 5625 23 AUG 27 | US87166FAE34 | Details |
Understaning Synaptogenix Use of Financial Leverage
Understanding the structure of Synaptogenix's debt obligations provides insight if it is worth investing in it. Financial leverage can amplify the potential profits to Synaptogenix's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its cost of debt.
Last Reported | Projected for Next Year | ||
Net Debt | -28.7 M | -30.1 M | |
Net Debt To EBITDA | 3.45 | 3.62 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Synaptogenix Stock Analysis
When running Synaptogenix's price analysis, check to measure Synaptogenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synaptogenix is operating at the current time. Most of Synaptogenix's value examination focuses on studying past and present price action to predict the probability of Synaptogenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synaptogenix's price. Additionally, you may evaluate how the addition of Synaptogenix to your portfolios can decrease your overall portfolio volatility.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.